drugset / Trial / NCT05934448
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this study are: \- Pembrolizumab Standard treatment will include: * CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel) * Cyclophosphamide * Fludarabine
Timeline
- Start
- 2023-11-15
- Primary completion
- 2027-06-06
- Completion
- 2031-06-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | Axicabtagene Ciloleucel | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Lisocabtagene Maraleucel | Cell therapy | — | — |